Ceremed has received a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health (NIH) to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents like Vancomycin directly to surgical sites.

Ceremed said that its anhydrous, soluble and highly malleable carrier is made of proprietary AOC material, which when applied to cut bone will control bleeding and release therapeutic agents as it dissolves without compromising the healing process.

The AOC formulation with Vancomycin, in combination with a carrier for the antibiotic Gentamicin, under development to an earlier NIH grant, will target both susceptible and methycillin-resistant (MRSA) organisms to help prevent post operative infections, reduce the cost of potentially preventable complications, and improve patient outcomes across surgical fields.

The third grant in the series was awarded for the development of an AOC carrier for DBM, which allows stable delivery of bone growth factors directly to the bone, strengthens bone fusion, and promotes earlier onset of healing and postoperative recovery without increased risk of complications.

Ceremed chairman Tadeusz Wellisz said that utilising the AOC material for delivery of therapeutics has great potential to continue improving patient outcomes across surgical fields and Ceremed has experienced success in developing soluble carriers for DBM and Gentamicin, and they look forward to continued success in the development of AOC Vancomycin.